Site Search

Can’t find what you’re looking for?

Showing 1-10 of 29 Results

* Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07) ** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development o

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07) ** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)

Department: Oncology

Diagnosis: Cancer - Oncology

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses with Placebo as Treatment for Rhinovirus (RV) in Participants with Chronic Obstructive Pulmonary Dis

Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial Comparing the Safety and Efficacy of Two Different Oral Vapendavir (VPV) Doses with Placebo as Treatment for Rhinovirus (RV) in Participants with Chronic Obstructive Pulmonary Disease (COPD)

Department: Pulmonary

Diagnosis: Pulmonary (Lung)

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2 Advanced Breast Cancer (OPERA-02)

Title: A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2 Advanced Breast Cancer (OPERA-02)

Department: Oncology

Diagnosis: Cancer - Breast

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Department: Oncology

Diagnosis: Cancer - Breast

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamou

Title: A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Department: Oncology

Diagnosis: Cancer - Lung

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)

Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)

Department: Pulmonary

Diagnosis: Pulmonary (Lung)

A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or witho

Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

Department: Oncology

Diagnosis: Cancer - Oncology

A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures

Department: Oncology

Diagnosis: Cancer - Oncology

A012103 OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Title: A012103 OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

Department: Oncology

Diagnosis: Cancer - Breast

ALLIANCE A032302 DOCETAXEL ADDITION IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (ASPIRE)

Title: ALLIANCE A032302 DOCETAXEL ADDITION IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (ASPIRE)

Department: Oncology

Diagnosis: Cancer - Oncology

Showing 1-10 of 29 Results